IL-21: A pleiotropic cytokine with potential applications in Oncology

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Croce, Michela ^a   Rigo, Valentina ^a   Ferrini, Silvano ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 21; TUMOR ANTIGEN; ANTINEOPLASTIC AGENT; IL10 PROTEIN, HUMAN; INTERLEUKIN 10; INTERLEUKIN 21; INTERLEUKIN DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DENDRITIC CELL; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSTIMULATION; INNATE IMMUNITY; LEUKEMIA; LYMPHOID CELL; LYMPHOMA; MOLECULARLY TARGETED THERAPY; NATURAL KILLER CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; T LYMPHOCYTE ACTIVATION; BIOSYNTHESIS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NEOPLASM; PROCEDURES; REGULATORY T LYMPHOCYTE; TH17 CELL;

ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES, REGULATORY; CELL PROLIFERATION; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-10; INTERLEUKINS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84928964205     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/696578     Document Type: Review

References (147)

1. K. Ozaki, K. Kikly, D. Michalovich, P. R. Young, and W. J. Leonard, "Cloning of a type I cytokine receptor most related to the IL-2 receptor chain, " Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 21, pp. 11439-11444, 2000.
2. J. Parrish-Novak, S. R. Dillon, A. Nelson et al., "Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function, " Nature, vol. 408, no. 6808, pp. 57-63, 2000.
3. Y. Rochman, R. Spolski, and W. J. Leonard, "New insights into the regulation of T cells by gammac family cytokines, " Nature Reviews Immunology, vol. 9, no. 7, pp. 480-490, 2009.
4. R. Meazza, B. Azzarone, A. M. Orengo, and S. Ferrini, "Role of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy, " Journal of Biomedicine and Biotechnology, vol. 2011, Article ID 861920, 16 pages, 2011.
5. R. Spolski and W. J. Leonard, "Interleukin-21: a double-edged swordwith therapeutic potential, " Nature Reviews Drug Discovery, vol. 13, no. 5, pp. 379-395, 2014.
6. K. Ghoreschi, A. Laurence, and J. J. O'Shea, "Janus kinases in immune cell signaling, " Immunological Reviews, vol. 228, no. 1, pp. 273-287, 2009.
7. R. Zeng, R. Spolski, E. Casas, W. Zhu, D. E. Levy, and W. J. Leonard, "Themolecular basis of IL-21-mediated proliferation, " Blood, vol. 109, no. 10, pp. 4135-4142, 2007.
8. D. de Totero, R. Meazza, M. Capaia et al., "The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways, " Blood, vol. 111, no. 2, pp. 517-524, 2008.
9. H. Kwon, D. Thierry-Mieg, J. Thierry-Mieg et al., "Analysis of interleukin-21-induced Prdm1 gene regulation reveals functional cooperation of STAT3 and IRF4 transcription factors, " Immunity, vol. 31, no. 6, pp. 941-952, 2009.
10. H. Jin, R. Carrio, A. Yu, and T. R. Malek, "Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis, " Journal of Immunology, vol. 173, no. 1, pp. 657-665, 2004.
11. S. A. Diehl, H. Schmidlin, M. Nagasawa et al., "STAT3-mediated Up-regulation of BLIMP1 is coordinated with BCL6 downregulation to control human plasma cell differentiation, " The Journal of Immunology, vol. 180, no. 7, pp. 4805-4815, 2008.
12. M. Strengell, A. Lehtonen, S. Matikainen, and I. Julkunen, "IL-21 enhances SOCS gene expression and inhibits LPS-induced cytokine production in human monocyte-derived dendritic cells, " Journal of Leukocyte Biology, vol. 79, no. 6, pp. 1279-1285, 2006.
13. B. Jahrsdörfer, S. E. Blackwell, J. E. Wooldridge et al., "B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation, " Blood, vol. 108, no. 8, pp. 2712-2719, 2006.
14. K. L. Good, V. L. Bryant, and S. G. Tangye, "Kinetics of human B cell behavior and amplification of proliferative responses following stimulation with IL-21, " Journal of Immunology, vol. 177, no. 8, pp. 5236-5247, 2006.
15. J. Pène, J.-F. Gauchat, S. Lécart et al., "Cutting edge: IL-21 is a switch factor for the production of IgG1 and IgG3 by human B cells, " The Journal of Immunology, vol. 172, no. 9, pp. 5154-5157, 2004.
16. L. Moens and S. G. Tangye, "Cytokine-mediated regulation of plasma cell generation: IL-21 takes center stage, " Frontiers in Immunology, vol. 5, article 65, 2014.
17. K. Ozaki, R. Spolski, C. G. Feng et al., "A critical role for IL-21 in regulating immunoglobulin production, " Science, vol. 298, no. 5598, pp. 1630-1634, 2002.
18. D. Kotlarz, N. Ziętara, G. Uzel et al., "Loss-of-function mutations in the IL-21 receptor gene cause a primary immunodeficiency syndrome, " Journal of Experimental Medicine, vol. 210, no. 3, pp. 433-443, 2013.
19. E. Salzer, A. Kansu, H. Sic et al., "Early-onset inflammatory bowel disease and common variable immunodeficiency-like disease caused by IL-21 deficiency, " Journal of Allergy and Clinical Immunology, vol. 133, no. 6, pp. 1651-1659, 2014.
20. K. Ozaki, R. Spolski, R. Ettinger et al., "Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6, " Journal of Immunology, vol. 173, no. 9, pp. 5361-5371, 2004.
21. D. Herber, T. P. Brown, S. Liang, D. A. Young, M. Collins, andK. Dunussi-Joannopoulos, "IL-21 has a pathogenic role in a lupusprone mouse model and its blockade with IL-21R. Fc reduces disease progression, " The Journal of Immunology, vol. 178, no. 6, pp. 3822-3830, 2007.
22. A. H. Sawalha, K. M. Kaufman, J. A. Kelly et al., "Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus, " Annals of the Rheumatic Diseases, vol. 67, no. 4, pp. 458-461, 2008.
23. H. Nakano, T. Kishida, H. Asada et al., "Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma, " The Journal of Gene Medicine, vol. 8, no. 1, pp. 90-99, 2006.
24. A. T. Bauquet, H. Jin, A. M. Paterson et al., "The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells, " Nature Immunology, vol. 10, no. 2, pp. 167-175, 2009.
25. R. I. Nurieva, Y. Chung, G. J. Martinez et al., "Bcl6mediates the development of T follicular helper cells, " Science, vol. 325, no. 5943, pp. 1001-1005, 2009.
26. N. Bollig, A. Brusütle, K. Kellner et al., "Transcription factor IRF4 determines germinal center formation through follicular T-helper cell differentiation, " Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 22, pp. 8664-8669, 2012.
27. P. T. Sage, D. Alvarez, J. Godec, U. H. von Andrian, and A. H. Sharpe, "CirculatingTfollicular regulatory and helper cells have memory-like properties, " Journal of Clinical Investigation, vol. 124, no. 12, pp. 5191-5204, 2014.
28. M. A. Linterman, R. J. Rigby, R. K. Wong et al., "Follicular helper T cells are required for systemic autoimmunity, " The Journal of Experimental Medicine, vol. 206, no. 3, pp. 561-576, 2009.
29. J. M. Odegard, B. R. Marks, L. D. Diplacido et al., "ICOSdependent extrafollicular helperTcells elicit IgGproduction via IL-21 in systemic autoimmunity, " The Journal of Experimental Medicine, vol. 205, no. 12, pp. 2873-2886, 2008.
30. L. Wei, A. Laurence, K. M. Elias, and J. J. O'Shea, "IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner, " Journal of Biological Chemistry, vol. 282, no. 48, pp. 34605-34610, 2007.
31. R. Nurieva, X. O. Yang, G. Martinez et al., "Essential autocrine regulation by IL-21 in the generation of inflammatory T cells, " Nature, vol. 448, no. 7152, pp. 480-483, 2007.
32. L. Zhou, I. I. Ivanov, R. Spolski et al., "IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways, " Nature Immunology, vol. 8, no. 9, pp. 967-974, 2007.
33. D. di Fusco, R. Izzo, M. M. Figliuzzi, F. Pallone, and G. Monteleone, "IL-21 as a therapeutic target in inflammatory disorders, " Expert Opinion on Therapeutic Targets, vol. 18, no. 11, pp. 1329-1338, 2014.
34. G. Monteleone, I. Monteleone, D. Fina et al., "Interleukin-21 enhances T-helper cell type I signaling and interferon-production in Crohn's disease, " Gastroenterology, vol. 128, no. 3, pp. 687-694, 2005.
35. M. Sarra, I. Monteleone, C. Stolfi et al., "Interferon-gammaexpressing cells are a major source of interleukin-21 in inflammatory bowel diseases, " Inflammatory Bowel Diseases, vol. 16, no. 8, pp. 1332-1339, 2010.
36. D. Fina, M. Sarra, M. C. Fantini et al., "Regulation of gut inflammation and Th17 cell response by interleukin-21, " Gastroenterology, vol. 134, no. 4, pp. 1038-1048, 2008.
37. Y. Li, M. Bleakley, and C. Yee, "IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response, " Journal of Immunology, vol. 175, no. 4, pp. 2261-2269, 2005.
38. N. L. Alves, F. A. Arosa, and R. A. W. van Lier, "IL-21 sustains CD28 expression on IL-15-activated human naive CD8+ Tcells, " The Journal of Immunology, vol. 175, no. 2, pp. 755-762, 2005.
39. R. Zeng, R. Spolski, S. E. Finkelstein et al., "Synergy of IL-21 and IL-15 in regulatingCD8+ T cell expansion and function, " Journal of Experimental Medicine, vol. 201, no. 1, pp. 139-148, 2005.
40. E. Di Carlo, D. de Totero, T. Piazza, M. Fabbi, and S. Ferrini, "Role of IL-21 in immune-regulation and tumor immunotherapy, " Cancer Immunology, Immunotherapy, vol. 56, no. 9, pp. 1323-1334, 2007.
41. A. P. R. Sutherland, N. Joller, M. Michaud, S. M. Liu, V. K. Kuchroo, andM. J. Grusby, "IL-21 promotesCD8+ CTL activity via the transcription factor T-bet, " The Journal of Immunology, vol. 190, no. 8, pp. 3977-3984, 2013.
42. J. Gagnon, S. Ramanathan, C. Leblanc, and S. Ilangumaran, "Regulation of IL-21 signaling by suppressor of cytokine signaling-1 (SOCS1) in CD8+ T lymphocytes, " Cellular Signalling, vol. 19, no. 4, pp. 806-816, 2007.
43. C. S. Hinrichs, R. Spolski, C. M. Paulos et al., "IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy, " Blood, vol. 111, no. 11, pp. 5326-5333, 2008.
44. E. M. M. van Leeuwen, J. D. vanBuul, E. B. M. Remmerswaal, P. L. Hordijk, I. J. M. ten Berge, and R. A. W. van Lier, "Functional re-expression of CCR7 on CMV-specific CD8+ T cells upon antigenic stimulation, " International Immunology, vol. 17, no. 6, pp. 713-719, 2005.
45. A. Fröhlich, J. Kisielow, I. Schmitz et al., "IL-21R on T cells is critical for sustained functionality and control of chronic viral infection, " Science, vol. 324, no. 5934, pp. 1576-1580, 2009.
46. H. Elsaesser, K. Sauer, and D. G. Brooks, "IL-21 is required to control chronic viral infection, " Science, vol. 324, no. 5934, pp. 1569-1572, 2009.
47. J. S. Yi, M. Du, and A. J. Zajac, "A vital role for Interleukin-21 in the control of a chronic viral infection, " Science, vol. 324, no. 5934, pp. 1572-1576, 2009.
48. A. Iannello, C. Tremblay, J.-P. Routy, M.-R. Boulassel, E. Toma, and A. Ahmad, "Decreased levels of circulating IL-21 in HIVinfected AIDS patients: correlation with CD4+ T-cell counts, " Viral Immunology, vol. 21, no. 3, pp. 385-388, 2008.
49. A. Iannello, M.-R. Boulassel, S. Samarani et al., "Dynamics and consequences of IL-21 production in HIV-infected individuals: a longitudinal and cross-sectional study, " The Journal of Immunology, vol. 184, no. 1, pp. 114-126, 2010.
50. M. F. Chevalier, B. Jülg, A. Pyo et al., "HIV-1-specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function, " Journal of Virology, vol. 85, no. 2, pp. 733-741, 2011.
51. L. White, S. Krishnan, N. Strbo et al., "Differential effects of IL-21 and IL-15 on perforin expression, lysosomal degranulation, and proliferation in CD8 T cells of patients with human immunodeficiency virus-1 (HIV), " Blood, vol. 109, no. 9, pp. 3873-3880, 2007.
52. L. D. Williams, A. Bansal, S. Sabbaj et al., "Interleukin-21-producing HIV-1-specific CD8 T cells are preferentially seen in elite controllers, " Journal of Virology, vol. 85, no. 5, pp. 2316-2324, 2011.
53. L. D. Williams, N. Amatya, A. Bansal et al., "Immune activation is associated with CD8 T cell interleukin-21 production in HIV-1-infected individuals, " Journal of Virology, vol. 88, no. 17, pp. 10259-10263, 2014.
54. J. A. Toomey, F. Gays, D. Foster, and C. G. Brooks, "Cytokine requirements for the growth and development of mouse NK cells in vitro, " Journal of Leukocyte Biology, vol. 74, no. 2, pp. 233-242, 2003.
55. J. Brady, Y. Hayakawa, M. J. Smyth, andS. L. Nutt, "IL-21 induces the functional maturation of murine NK cells, " The Journal of Immunology, vol. 172, no. 4, pp. 2048-2058, 2004.
56. M. T. Kasaian, M. J. Whitters, L. L. Carter et al., "IL-21 limitsNK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity, " Immunity, vol. 16, no. 4, pp. 559-569, 2002.
57. S. Zhu, P. V. Phatarpekar, C. J. Denman et al., "Transcription of the activating receptorNKG2Din natural killer cells is regulated by STAT3 tyrosine phosphorylation, " Blood, vol. 124, no. 3, pp. 403-411, 2014.
58. S. Sivori, C. Cantoni, S. Parolini et al., "IL-21 induces both rapid maturation of human CD34+ cell precursors towards NK cells and acquisition of surface killer Ig-like receptors, " European Journal of Immunology, vol. 33, no. 12, pp. 3439-3447, 2003.
59. C. A. J. Vosshenrich, T. Ranson, S. I. Samson et al., "Roles for common cytokine receptor-chain-dependent cytokines in the generation, differentiation, and maturation of NK cell precursors and peripheral NK cells in vivo, " The Journal of Immunology, vol. 174, no. 3, pp. 1213-1221, 2005.
60. M. Watanabe, K. Kono, Y. Kawaguchi et al., "Interleukin-21 can efficiently restore impaired antibody-dependent cellmediated cytotoxicity in patients with oesophageal squamous cell carcinoma, " British Journal ofCancer, vol. 102, no. 3, pp. 520-529, 2010.
61. J. M. Roda, T. Joshi, J. P. Butchar et al., "The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor-positive tumor cells is enhanced by cytokines, " Clinical Cancer Research, vol. 13, no. 21, pp. 6419-6428, 2007.
62. K. Brandt, S. Bulfone-Paus, A. Jenckel, D. C. Foster, R. Paus, and R. Rückert, "Interleukin-21 inhibits dendritic cell-mediated T cell activation and induction of contact hypersensitivity in vivo, " Journal of Investigative Dermatology, vol. 121, no. 6, pp. 1379-1382, 2003.
63. C.-K. Wan, J. Oh, P. Li et al., "The cytokines IL-21 and GM-CSF have opposing regulatory roles in the apoptosis of conventional dendritic cells, " Immunity, vol. 38, no. 3, pp. 514-527, 2013.
64. R. Spolski, H.-P. Kim, W. Zhu, D. E. Levy, and W. J. Leonard, "IL-21 mediates suppressive effects via its induction of IL-10, " The Journal of Immunology, vol. 182, no. 5, pp. 2859-2867, 2009.
65. K. W. Moore, R. De Waal Malefyt, R. L. Coffman, and A. O'Garra, "Interleukin-10 and the interleukin-10 receptor, " Annual Review of Immunology, vol. 19, pp. 683-765, 2001.
66. J. O. Jin, X. Han, and Q. Yu, "Interleukin-6 induces the generation of IL-10-producing Tr1 cells and suppresses autoimmune tissue inflammation, " Journal of Autoimmunity, vol. 40, no. 1, pp. 28-44, 2013.
67. A. Doganci, J. Birkholz, S. Gehring, A. G. Puhl, F. Zepp, and C. U. Meyer, "In the presence of IL-21 human cord blood T cells differentiate to IL-10-producing Th1 but not Th17 orTh2 cells, " International Immunology, vol. 25, no. 3, pp. 157-169, 2013.
68. C. Pot, H. Jin, A. Awasthi et al., "Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells, " The Journal of Immunology, vol. 183, no. 2, pp. 797-801, 2009.
69. Y. He, H. Qian, Y. Liu, L. Duan, Y. Li, and G. Shi, "The roles of regulatory B cells in cancer, " Journal of Immunology Research, vol. 2014, Article ID 215471, 7 pages, 2014.
70. A. Yoshizaki, T. Miyagaki, D. J. Dilillo et al., "Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions, " Nature, vol. 491, no. 7423, pp. 264-268, 2012.
71. S. Lindner, K. Dahlke, K. Sontheimer et al., "Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells, " Cancer Research, vol. 73, no. 8, pp. 2468-2479, 2013.
72. A. Comes, O. Rosso, A. M. Orengo et al., "CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine, " Journal of Immunology, vol. 176, no. 3, pp. 1750-1758, 2006.
73. I. Peluso, M. C. Fantini, D. Fina et al., "IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes, " Journal of Immunology, vol. 178, no. 2, pp. 732-739, 2007.
74. K. Attridge, C. J. Wang, L. Wardzinski et al., "IL-21 inhibits T cell IL-2 production and impairs Treg homeostasis, " Blood, vol. 119, no. 20, pp. 4656-4664, 2012.
75. A. Battaglia, A. Buzzonetti, C. Baranello et al., "Interleukin-21 (IL-21) synergizes with IL-2 to enhance T-cell receptorinduced human T-cell proliferation and counteracts IL-2/transforming growth factor-induced regulatory T-cell development, " Immunology, vol. 139, no. 1, pp. 109-120, 2013.
76. B. Terrier, G. Geri, W. Chaara et al., "Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis, " Arthritis & Rheumatism, vol. 64, no. 6, pp. 2001-2011, 2012.
77. F. Hua, G. M. Comer, L. Stockert et al., "Anti-IL21 receptor monoclonal antibody (ATR-107): safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase 1, first-in-human study, "The Journal of Clinical Pharmacology, vol. 54, no. 1, pp. 14-22, 2014.
78. C. G. McPhee, J. A. Bubier, T. J. Sproule et al., "IL-21 is a doubleedged sword in the systemic lupus erythematosus-like disease of BXSB. Yaa mice, " The Journal of Immunology, vol. 191, no. 9, pp. 4581-4588, 2013.
79. J. Ma, D. Ma, and C. Ji, "The role of IL-21 in hematological malignancies, " Cytokine, vol. 56, no. 2, pp. 133-139, 2011.
80. S. Zhang and T. J. Kipps, "The pathogenesis of chronic lymphocytic leukemia, " Annual Review of Pathology: Mechanisms of Disease, vol. 9, pp. 103-118, 2014.
81. J. A. Burger and J. G. Gribben, "The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies, " Seminars in Cancer Biology, vol. 24, pp. 71-81, 2014.
82. D. De Totero, R. Meazza, S. Zupo et al., "Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells, " Blood, vol. 107, no. 9, pp. 3708-3715, 2006.
83. A. Gowda, J. Roda, S.-R. A. Hussain et al., "IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro, " Blood, vol. 111, no. 9, pp. 4723-4730, 2008.
84. M. Hagn, S. E. Blackwell, T. Beyer et al., "B-CLL cells acquire APC-and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21, " International Immunology, vol. 26, no. 7, pp. 383-395, 2014.
85. M. F. Pascutti, M. Jak, J. M. Tromp et al., "IL-21 and CD40L signals fromautologous T cells can induce antigen-independent proliferation of CLL cells, " Blood, vol. 122, no. 17, pp. 3010-3019, 2013.
86. M. J. Ahearne, S. Willimott, L. Pinon et al., "Enhancement of CD154/IL4 proliferation by the T follicular helper (Tfh) cytokine, IL21 and increased numbers of circulating cells resembling Tfh cells in chronic lymphocytic leukaemia, " British Journal of Haematology, vol. 162, no. 3, pp. 360-370, 2013.
87. N. Akamatsu, Y. Yamada, H. Hasegawa et al., "High IL-21 receptor expression and apoptosis induction by IL-21 in follicular lymphoma, " Cancer Letters, vol. 256, no. 2, pp. 196-206, 2007.
88. D. de Totero, M. Capaia, M. Fabbi et al., "Heterogeneous expression and function of IL-21R and susceptibility to IL-21-mediated apoptosis in follicular lymphoma cells, " Experimental Hematology, vol. 38, no. 5, pp. 373-383, 2010.
89. B. Wood, S. Sikdar, S. J. Choi et al., "Abundant expression of interleukin-21 receptor in follicular lymphoma cells is associated with more aggressive disease, "Leukemia&Lymphoma, vol. 54, no. 6, pp. 1212-1220, 2013.
90. K. A. Sarosiek, R. Malumbres, H. Nechushtan, A. J. Gentles, E. Avisar, and I. S. Lossos, "Novel IL-21 signaling pathway upregulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas, " Blood, vol. 115, no. 3, pp. 570-580, 2010.
91. P. Gelebart, Z. Zak, M. Anand, J. Dien-Bard, H. M. Amin, and R. Lai, "Interleukin-21 effectively induces apoptosis in mantle cell lymphoma through a STAT1-dependent mechanism, " Leukemia, vol. 23, no. 10, pp. 1836-1846, 2009.
92. J. D. Bard, P. Gelebart, M. Anand et al., "IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALKpositive anaplastic large cell lymphoma, " American Journal of Pathology, vol. 175, no. 2, pp. 825-834, 2009.
93. F. A. Scheeren, S. A. Diehl, L. A. Smit et al., "IL-21 is expressed in Hodgkin lymphoma and activates STAT5: evidence that activated STAT5 is required for Hodgkin lymphomagenesis, " Blood, vol. 111, no. 9, pp. 4706-4715, 2008.
94. A.-T. Brenne, T. B. Ro, A. Waage, A. Sundan, M. Borset, andH. Hjorth-Hansen, "Interleukin-21 is a growth and survival factor for human myeloma cells, " Blood, vol. 99, no. 10, pp. 3756-3762, 2002.
95. E. Ménoret, S. Mäga, G. Descamps et al., "IL-21 stimulates human myeloma cell growth through an autocrine IGF-1 loop, " TheJournal of Immunology, vol. 181, no. 10, pp. 6837-6842, 2008.
96. L. S. Hodge, S. C. Ziesmer, Z. Z. Yang et al., "IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia, " Blood, vol. 120, no. 18, pp. 3774-3782, 2012.
97. M. Ueda, K. Imada, A. Imura, H. Koga, M. Hishizawa, and T. Uchiyama, "Expression of functional interleukin-21 receptor on adult T-cell leukaemia cells, " British Journal ofHaematology, vol. 128, no. 2, pp. 169-176, 2005.
98. M. Marzec, X. Liu, M. Wysocka, A. H. Rook, N. Odum, and M. A. Wasik, "Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) andMNKinduces apoptosis of cutaneous T-cell Lymphoma (CTCL) cells, " PLoS ONE, vol. 6, no. 9, Article ID e24849, 2011.
99. L. van der Fits, J. J. Out-Luiting, C. P. Tensen, W. H. Zoutman, and M. H. Vermeer, "Exploring the IL-21-STAT3 axis as therapeutic target for Sézary syndrome, " Journal of Investigative Dermatology, vol. 134, no. 10, pp. 2639-2647, 2014.
100. E. di Carlo, A. Comes, A. M. Orengo et al., "IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice, "TheJournal of Immunology, vol. 172, no. 3, pp. 1540-1547, 2004.
101. H.-L. Ma, M. J. Whitters, R. F. Konz et al., "IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFNgamma, " The Journal of Immunology, vol. 171, no. 2, pp. 608-615, 2003.
102. S.-I. Ugai, O. Shimozato, K. Kawamura et al., "Expression of the interleukin-21 gene in murine colon carcinoma cells generates systemic immunity in the inoculated hosts, " Cancer GeneTherapy, vol. 10, no. 3, pp. 187-192, 2003.
103. M. Kumano, I. Hara, J. Furukawa et al., "Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response inmouse renal cell carcinoma, " The Journal of Urology, vol. 178, no. 4, pp. 1504-1509, 2007.
104. J. Furukawa, I. Hara, H. Nagai, A. Yao, S. Oniki, and M. Fujisawa, "Interleukin-21 gene transfection into mouse bladder cancer cells results in tumor rejection through the cytotoxic T lymphocyte response, " Journal of Urology, vol. 176, no. 3, pp. 1198-1203, 2006.
105. A. Daga, A. M. Orengo, R. M. R. Gangemi et al., "Glioma immunotherapy by IL-21 gene-modified cells or by recombinant IL-21 involves antibody responses, " International Journal of Cancer, vol. 121, no. 8, pp. 1756-1763, 2007.
106. J. Dou, Y. Wu, J. Wang et al., "Eliciting protective immune responses against murine myeloma challenge in lymphopenia mice through adoptive transfer of tumor antigen-specific lymphocytes and immunization of tumor vaccine secreting mIL-21, " Cancer Gene Therapy, vol. 17, no. 10, pp. 675-683, 2010.
107. K. Aravindaram, P.-H. Wang, S.-Y. Yin, and N.-S. Yang, "Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma, " GeneTherapy, vol. 21, no. 5, pp. 457-467, 2014.
108. W. Hu, J. Wang, J. Dou et al., "Augmenting therapy of ovarian cancer efficacy by secreting IL-21 human umbilical cord blood stem cells in nude mice, " Cell Transplantation, vol. 20, no. 5, pp. 669-680, 2011.
109. A. Moroz, C. Eppolito, Q. Li, J. Tao, C. H. Clegg, and P. A. Shrikant, "IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21, " The Journal of Immunology, vol. 173, no. 2, pp. 900-909, 2004.
110. H. Søndergaard, E. D. Galsgaard, M. Bartholomaeussen, P. T. Straten, N. ∅dum, and K. Skak, "Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ Tcell density and activity, and enlarges draining lymph nodes, " Journal of Immunotherapy, vol. 33, no. 3, pp. 236-249, 2010.
111. P. V. Sivakumar, R. Garcia, K. S. Waggie, M. Anderson-Haley, A. Nelson, and S. D. Hughes, "Comparison of vascular leak syndrome in mice treated with IL21 or IL2, " Comparative Medicine, vol. 63, no. 1, pp. 13-21, 2013.
112. K. Skak, M. Kragh, D. Hausman, M. J. Smyth, and P. V. Sivakumar, "Interleukin 21: combination strategies for cancer therapy, " Nature Reviews Drug Discovery, vol. 7, no. 3, pp. 231-240, 2008.
113. T. L. Whiteside, "Clinical impact of regulatory T cells (Treg) in cancer and HIV, " Cancer Microenvironment, 2014.
114. M. P. Colombo and S. Piconese, "Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy, " Nature Reviews Cancer, vol. 7, no. 11, pp. 880-887, 2007.
115. M. Croce, M. V. Corrias, A. M. Orengo et al., "Transient depletion of CD4+ T cells augments IL-21-based immunotherapy of disseminated neuroblastoma in syngeneic mice, " International Journal of Cancer, vol. 127, no. 5, pp. 1141-1150, 2010.
116. V. Rigo, M. V. Corrias, A. M. Orengo et al., "Recombinant IL-21 and anti-CD4 antibodies cooperate in syngeneic neuroblastoma immunotherapy and mediate long-lasting immunity, " Cancer Immunology, Immunotherapy, vol. 63, no. 5, pp. 501-511, 2014.
117. D. M. Pardoll, "The blockade of immune checkpoints in cancer immunotherapy, " Nature Reviews Cancer, vol. 12, no. 4, pp. 252-264, 2012.
118. X.-C. Pan, L. Li, J.-J. Mao et al., "Synergistic effects of soluble PD-1 and IL-21 on antitumor immunity against H22 murine hepatocellular carcinoma, " Oncology Letters, vol. 5, no. 1, pp. 90-96, 2013.
119. M. Jure-Kunkel, G. Masters, E. Girit et al., "Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models, " Cancer Immunology, Immunotherapy, vol. 62, no. 9, pp. 1533-1545, 2013.
120. M. J. Smyth, M. W. L. Teng, J. Sharkey et al., "Interleukin 21 enhances antibody-mediated tumor rejection, " Cancer Research, vol. 68, no. 8, pp. 3019-3025, 2008.
121. J. M. Roda, R. Parihar, A. Lehman, A. Mani, S. Tridandapani, and W. E. Carson III, "Interleukin-21 enhances NK cell activation in response to antibody-coated targets, " The Journal of Immunology, vol. 177, no. 1, pp. 120-129, 2006.
122. C. M. Krejsa, R. D. Holly, M. Heipel et al., "Interleukin-21 enhances rituximab activity in a cynomolgus monkey model of B cell depletion and in mouse B cell lymphoma models, " PLoS ONE, vol. 8, no. 6, Article ID e67256, 2013.
123. J. Dou, Y. Wang, J. Wang et al., "Antitumor efficacy induced by human ovarian cancer cells secreting IL-21 alone or combination with GM-CSF cytokines in nude mice model, " Immunobiology, vol. 214, no. 6, pp. 483-492, 2009.
124. F. Zhao, J. Dou, X. F. He et al., "Enhancing therapy of B16F10 melanoma efficacy through tumor vaccine expressing GPIanchored IL-21 and secreting GM-CSF in mouse model, " Vaccine, vol. 28, no. 16, pp. 2846-2852, 2010.
125. X. He, J. Wang, F. Zhao et al., "ESAT-6-gpi DNA vaccine augmented the specific antitumour efficacy induced by the tumour vaccine B16F10-ESAT-6-gpi/IL-21 in a mouse model, " Scandinavian Journal of Immunology, vol. 78, no. 1, pp. 69-78, 2013.
126. A. Kowalczyk, A. Wierzbicki, M. Gil et al., "Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery, " Cancer Immunology, Immunotherapy, vol. 56, no. 9, pp. 1443-1458, 2007.
127. R. Wu, M.-A. Forget, J. Chacon et al., "Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook, " The Cancer Journal, vol. 18, no. 2, pp. 160-175, 2012.
128. Y. Li, S. Liu, J. Hernandez, L. Vence, P. Hwu, and L. Radvanyi, "MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro, " The Journal of Immunology, vol. 184, no. 1, pp. 452-465, 2010.
129. H. Singh, M. J. Figliola, M. J. Dawson et al., "Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies, " Cancer Research, vol. 71, no. 10, pp. 3516-3527, 2011.
130. S. Yang, Y. Ji, L. Gattinoni et al., "Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails, " Cancer Immunology, Immunotherapy, vol. 62, no. 4, pp. 727-736, 2013.
131. A. G. Chapuis, G. B. Ragnarsson, H. N. Nguyen et al., "Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients, " Science Translational Medicine, vol. 5, no. 174, 2013.
132. A. Thedrez, C. Harly, A. Morice, S. Salot, M. Bonneville, and E. Scotet, "IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human Vgamma9Vdelta2 T cells for adoptive immunotherapy, " The Journal of Immunology, vol. 182, no. 6, pp. 3423-3431, 2009.
133. B. Jiang, X. Wu, X.-N. Li et al., "Expansion of NK cells by engineered K562 cells co-expressing 4-1BBL and mMICA, combined with soluble IL-21, "Cellular Immunology, vol. 290, no. 1, pp. 10-20, 2014.
134. C. J. Denman, V. V. Senyukov, S. S. Somanchi et al., "Membranebound IL-21 promotes sustained ex vivo proliferation of human natural killer cells, " PLoS ONE, vol. 7, no. 1, Article ID e30264, 2012.
135. X. Wang, D. A. Lee, Y. Wang et al., "Membrane-bound interleukin-21 and CD137 ligand induce functional human natural killer cells from peripheral blood mononuclear cells through STAT-3 activation, " Clinical & Experimental Immunology, vol. 172, no. 1, pp. 104-112, 2013.
136. I. D. Davis, B. K. Skrumsager, J. Cebon et al., "An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma, " Clinical Cancer Research, vol. 13, no. 12, pp. 3630-3636, 2007.
137. I. D. Davis, B. Brady, R. F. Kefford et al., "Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IVMalignant melanoma without prior treatment: a phase IIa trial, " Clinical Cancer Research, vol. 15, no. 6, pp. 2123-2129, 2009.
138. J. A. Thompson, B. D. Curti, B. G. Redman et al., "Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma, " Journal of Clinical Oncology, vol. 26, no. 12, pp. 2034-2039, 2008.
139. M. G. Dodds, K. S. Frederiksen, K. Skak et al., "Immune activation in advanced cancer patients treated with recombinant IL-21: multianalyte profiling of serum proteins, " Cancer Immunology, Immunotherapy, vol. 58, no. 6, pp. 843-854, 2009.
140. H. Schmidt, J. Brown, U. Mouritzen et al., "Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial, " Clinical Cancer Research, vol. 16, no. 21, pp. 5312-5319, 2010.
141. T. M. Petrella, R. Tozer, K. Belanger et al., "Interleukin-21 has activity in patients with metastatic melanoma: a phase II study, " Journal of Clinical Oncology, vol. 30, no. 27, pp. 3396-3401, 2012.
142. T. M. Petrella, C. L. D. Mihalcioiu, E. McWhirter et al., "Final efficacy results of NCIC CTG IND. 202: a randomized phase II study of recombinant interleukin-21 (rIL21) in patients with recurrent or metastatic melanoma (MM), " Journal of Clinical Oncology, vol. 31, 2013, ASCO Meeting 2013, Abstract 9032.
143. J. M. Timmerman, J. C. Byrd, D. J. Andorsky et al., "A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders, " Clinical Cancer Research, vol. 18, no. 20, pp. 5752-5760, 2012.
144. N. Steele, A. Anthony, M. Saunders et al., "A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer, " British Journal of Cancer, vol. 106, no. 5, pp. 793-798, 2012.
145. V. Grünwald, I. M. E. Desar, J. Haanen et al., "A Phase i study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC), " Acta Oncologica, vol. 50, no. 1, pp. 121-126, 2011.
146. S. Bhatia, B. Curti, M. S. Ernstoff et al., "Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study, " Journal for ImmunoTherapy of Cancer, vol. 2, article 2, 2014.
147. M. Croce, R. Meazza, A. M. Orengo et al., "Immunotherapy of neuroblastoma by an Interleukin-21-secreting cell vaccine involves survivin as antigen, " Cancer Immunology, Immunotherapy, vol. 57, no. 11, pp. 1625-1634, 2008.